CN114502728A - 改进的尿酸酶及其用于治疗高尿酸血症的方法 - Google Patents

改进的尿酸酶及其用于治疗高尿酸血症的方法 Download PDF

Info

Publication number
CN114502728A
CN114502728A CN202080070950.5A CN202080070950A CN114502728A CN 114502728 A CN114502728 A CN 114502728A CN 202080070950 A CN202080070950 A CN 202080070950A CN 114502728 A CN114502728 A CN 114502728A
Authority
CN
China
Prior art keywords
seq
amino acid
uricase
variant
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080070950.5A
Other languages
English (en)
Inventor
黄国锋
赵朋
陈思
李铁
李瑞胜
张静
周岳华
刘洪川
姚盛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Junshi Biosciences Co Ltd
Suzhou Junmeng Biosciences Co Ltd
Original Assignee
Shanghai Junshi Biosciences Co Ltd
Suzhou Junmeng Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Junshi Biosciences Co Ltd, Suzhou Junmeng Biosciences Co Ltd filed Critical Shanghai Junshi Biosciences Co Ltd
Publication of CN114502728A publication Critical patent/CN114502728A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12N9/0048—Uricase (1.7.3.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

提供了改进的尿酸酶及其治疗高尿酸血症的方法以及包含该尿酸酶的药物组合物。该改进的尿酸酶包含与SEQ ID NO:1具有至少约90％的一致性的氨基酸序列，且所述序列不是SEQ ID NO:1。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN202080070950.5A 2019-10-11 2020-10-10 改进的尿酸酶及其用于治疗高尿酸血症的方法 Pending CN114502728A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019109643254 2019-10-11
CN201910964325.4A CN112646790A (zh) 2019-10-11 2019-10-11 改进的尿酸酶及其用于治疗高尿酸血症的方法
PCT/CN2020/120133 WO2021068925A1 (zh) 2019-10-11 2020-10-10 改进的尿酸酶及其用于治疗高尿酸血症的方法

Publications (1)

Publication Number Publication Date
CN114502728A true CN114502728A (zh) 2022-05-13

Family

ID=75342725

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910964325.4A Pending CN112646790A (zh) 2019-10-11 2019-10-11 改进的尿酸酶及其用于治疗高尿酸血症的方法
CN202080070950.5A Pending CN114502728A (zh) 2019-10-11 2020-10-10 改进的尿酸酶及其用于治疗高尿酸血症的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201910964325.4A Pending CN112646790A (zh) 2019-10-11 2019-10-11 改进的尿酸酶及其用于治疗高尿酸血症的方法

Country Status (9)

Country Link
US (1) US20230073183A1 (zh)
EP (1) EP4043559A1 (zh)
JP (1) JP2022553648A (zh)
KR (1) KR20220078647A (zh)
CN (2) CN112646790A (zh)
AU (1) AU2020362820A1 (zh)
BR (1) BR112022005757A2 (zh)
CA (1) CA3153029A1 (zh)
WO (1) WO2021068925A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112646790A (zh) * 2019-10-11 2021-04-13 上海君实生物医药科技股份有限公司 改进的尿酸酶及其用于治疗高尿酸血症的方法
CN115197922B (zh) * 2021-04-09 2024-05-14 派格生物医药(苏州)股份有限公司 尿酸酶或其同功异型物及其制备方法
WO2022214086A1 (zh) * 2021-04-09 2022-10-13 上海君实生物医药科技股份有限公司 尿酸酶、其药物组合物及其用途
WO2023064732A1 (en) * 2021-10-15 2023-04-20 Georgia State University Research Foundation, Inc. Delivery of therapeutic recombinant uricase using nanoparticles
CN117230034A (zh) * 2023-10-16 2023-12-15 临沂大学 一种高稳定性哺乳动物尿酸氧化酶突变体

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060188971A1 (en) * 1998-08-06 2006-08-24 Duke University Urate oxidase
CN101875922A (zh) * 2009-04-30 2010-11-03 重庆医科大学 来自苛求芽孢杆菌的两种尿酸酶和其突变体及它们的聚乙二醇修饰与应用
CN105543187A (zh) * 2016-02-18 2016-05-04 重庆医科大学 苛求芽孢杆菌尿酸酶突变体v145a
KR101637010B1 (ko) * 2015-04-24 2016-07-07 광주과학기술원 위치 특이적으로 알부민이 연결된 요산 산화효소 및 단백질에 위치 특이적으로 알부민을 연결하는 방법
CN107614007A (zh) * 2015-05-15 2018-01-19 免疫医疗有限责任公司 改进的尿酸酶序列和治疗方法
US20180282707A1 (en) * 2015-09-29 2018-10-04 Shanghai Institute Of Biological Products Co., Ltd. Mutant-type uricase, peg modified mutant-type uricase, and application thereof
US20200071681A1 (en) * 2017-07-07 2020-03-05 Allena Pharmaceuticals, Inc. Recombinant uricase enzyme
CN112646790A (zh) * 2019-10-11 2021-04-13 上海君实生物医药科技股份有限公司 改进的尿酸酶及其用于治疗高尿酸血症的方法
CN115197923A (zh) * 2021-04-09 2022-10-18 上海君实生物医药科技股份有限公司 尿酸酶、其药物组合物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69942834D1 (de) * 1998-08-06 2010-11-18 Univ Duke Harnsäureoxidase
HUE052976T2 (hu) * 2005-04-11 2021-06-28 Horizon Pharma Rheumatology Llc Urát-oxidáz variáns formái és azok alkalmazása

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060188971A1 (en) * 1998-08-06 2006-08-24 Duke University Urate oxidase
CN101875922A (zh) * 2009-04-30 2010-11-03 重庆医科大学 来自苛求芽孢杆菌的两种尿酸酶和其突变体及它们的聚乙二醇修饰与应用
KR101637010B1 (ko) * 2015-04-24 2016-07-07 광주과학기술원 위치 특이적으로 알부민이 연결된 요산 산화효소 및 단백질에 위치 특이적으로 알부민을 연결하는 방법
CN107614007A (zh) * 2015-05-15 2018-01-19 免疫医疗有限责任公司 改进的尿酸酶序列和治疗方法
US20180282707A1 (en) * 2015-09-29 2018-10-04 Shanghai Institute Of Biological Products Co., Ltd. Mutant-type uricase, peg modified mutant-type uricase, and application thereof
CN105543187A (zh) * 2016-02-18 2016-05-04 重庆医科大学 苛求芽孢杆菌尿酸酶突变体v145a
US20200071681A1 (en) * 2017-07-07 2020-03-05 Allena Pharmaceuticals, Inc. Recombinant uricase enzyme
CN112646790A (zh) * 2019-10-11 2021-04-13 上海君实生物医药科技股份有限公司 改进的尿酸酶及其用于治疗高尿酸血症的方法
CN115197923A (zh) * 2021-04-09 2022-10-18 上海君实生物医药科技股份有限公司 尿酸酶、其药物组合物及其用途

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANDREW C. NYBORG 等: "A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties", PLOS ONE, vol. 11, no. 12, 21 December 2016 (2016-12-21), pages 1 - 23, XP055880050, DOI: 10.1371/journal.pone.0167935 *
ELLA CZARINA MAGAT JUAN 等: "Structures of Arthrobacter globiformis urate oxidase–ligand complexes", BIOLOGICAL, vol. 64, no. 8, pages 815 - 822, XP009540260, DOI: 10.1107/S0907444908013590 *
HOSSAIN, M.T.: "Chain A, Revision History:~JUN 28 5 Initial Entry", GENBANK DATABASE, pages 1 *
JUAN, E.C.: "RecName: Full=Uricase; AltName: Full=Urate oxidase; Short=AgUOX", GENBANK DATABASE, 24 June 2015 (2015-06-24), pages 0 *
YI SHI 等: "Structure-based design of a hyperthermostable AgUricase for hyperuricemia and gout therapy", ACTA PHARMACOL SIN, vol. 40, no. 10, 28 June 2019 (2019-06-28), pages 1364 - 1372, XP036895200, DOI: 10.1038/s41401-019-0269-x *
YI-CHIH CHIU 等: "Structures of Arthrobacter globiformis urate oxidase–ligand complexes", BIOLOGICAL, vol. 188, 21 September 2009 (2009-09-21), pages 815 - 822 *
李想: "苛求芽孢杆菌尿酸酶的重组表达及其N端序列与功能关系的初步探讨", 中国优秀硕士学位论文全文数据库（电子期刊）, no. 3, pages 1 - 52 *

Also Published As

Publication number Publication date
EP4043559A1 (en) 2022-08-17
CN112646790A (zh) 2021-04-13
KR20220078647A (ko) 2022-06-10
JP2022553648A (ja) 2022-12-26
BR112022005757A2 (pt) 2022-06-21
WO2021068925A1 (zh) 2021-04-15
US20230073183A1 (en) 2023-03-09
AU2020362820A1 (en) 2022-05-05
CA3153029A1 (en) 2021-04-15

Similar Documents

Publication Publication Date Title
CN114502728A (zh) 改进的尿酸酶及其用于治疗高尿酸血症的方法
US20240026327A1 (en) Ph20 polypeptide variants, formulations and uses thereof
US11584949B2 (en) Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations thereof
KR102076348B1 (ko) 사람 아르기나제 및 부위-지향성 페길화된 사람 아르기나제 및 그의 용도
KR102244750B1 (ko) 치료적 목적을 위한 조작된 영장류 ｌ-메티오니나제
US20150010529A1 (en) Thermally stable ph20 hyaluronidase variants and uses thereof
KR102269209B1 (ko) 항신생물제로서 조작된 영장류 시스틴/시스테인 분해 효소
US20190048327A1 (en) Uricase sequences and methods of treatment
US20210386838A1 (en) Human-enzyme mediated depletion of homocysteine for treating patients with hyperhomocysteinemia and homocystinuria
KR20190026813A (ko) 시스틴의 인간-효소 매개된 고갈
JP2017205120A (ja) コリンエステラーゼ部分とポリマーとのコンジュゲート
CN106554948A (zh) 突变型尿酸酶、peg修饰的突变型尿酸酶及其应用
WO2022214086A1 (zh) 尿酸酶、其药物组合物及其用途
CN109652400A (zh) 抗癌药物精氨酸脱亚胺酶半衰期的分子改造方法及突变株

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination